Emergent Biosolutions Inc. | Key People and Executives
Fuad El-Hibri
Executive Chairman
Daniel J. Abdun-Nabi
Chief Executive Officer & Director
Sue Bailey
Independent Director
Louis Wade Sullivan
Independent Director
Ronald B. Richard
Lead Independent Director
Kathryn C. Zoon
Independent Director
Jerome M. Hauer
Independent Director
George A. Joulwan
Independent Director
Zsolt Pál Harsányi
Independent Director
Fuad El Hibri
Executive Chairman
Robert G. Kramer
President & Chief Operating Officer
Daniel J. Abdun-Nabi
Chief Executive Officer & Director
Richard S. Lindahl
Chief Financial Officer, Treasurer & Executive VP
Sharon M. Solomon
Chief Information Officer & Senior Vice President
W. James Jackson
Chief Scientific Officer & Senior Vice President
Barbara Solow
Senior Vice President-Research & Development
Adam R. Havey
Executive VP- Business Operations
John H. Ducote
Senior Vice President-Global Quality
Laura K. Kennedy
Senior VP, Chief Ethics & Compliance Officer
Darren W. Buchwald
Senior Vice President-Sales & Marketing
Lynn R. Kieffer
Vice President-Corporate Communications
Tracey Schmitt Lintott
Senior Vice President-Global Public Affairs
Robert G. Burrows
Vice President-Investor Relations
Katherine Strei
Chief Human Resources Officer & Executive VP
Atul Saran
Secretary & Executive VP-Corporate Development
Christopher W. Frech
Senior VP-Global Government Affairs
Sue Bailey
Independent Director
Louis Wade Sullivan
Independent Director
Ronald B. Richard
Lead Independent Director
Kathryn C. Zoon
Independent Director
Jerome M. Hauer
Independent Director
George A. Joulwan
Independent Director
Zsolt Pál Harsányi
Independent Director
| Address |
400 Professional Drive
Gaithersburg Maryland 20879
United States
|
|
Employees
|
- |
| Website |
http://www.emergentbiosolutions.com |
| Updated |
07/08/2019 |
| Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. |
